



Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081
Fax: 040 30211602
Email: neuland@neulandlabs.com
www.neulandlabs.com

December 13, 2017

To
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001
Scrip Code: 524558

To
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001
Scrip Code: NEULANLAB
Series: EQ

Dear Sirs,

Further to our letter dated Dec
please find enclosed a copy of t
s being uploaded on the websit

Sub: Press Release

This is for your information and the Press release being issued by the Company. The same
Thanking you, e of the Company.

Yours faithfully,

Records.

For Neuland Laboratories Limited


Garada Bhamidipati
Company Secretary

Incl : as above



Neuland acquires ~197 KL Advanced Intermediates and API Facility near Hyderabad

Hyderabad, India, December 13, 2017 - Neuland Laboratories Limited ("Neuland" or "Company" (NSE: NEULANDLAB* BSE+S, #524558). The Company has acquired a ~197 KL Advanced Intermediates and API Facility (API Facility) near Hyderabad, India. The facility is owned by a private entity and is currently being operated by a private entity. The facility is located in the Hyderabad region and is expected to be operational by the end of the year. The acquisition is expected to enhance the Company's manufacturing capabilities and expand its product portfolio.

The facility is expected to be operational by the end of the year. The acquisition is expected to enhance the Company's manufacturing capabilities and expand its product portfolio. The facility is located in the Hyderabad region and is expected to be operational by the end of the year. The acquisition is expected to enhance the Company's manufacturing capabilities and expand its product portfolio.

The facility is expected to be operational by the end of the year. The acquisition is expected to enhance the Company's manufacturing capabilities and expand its product portfolio. The facility is located in the Hyderabad region and is expected to be operational by the end of the year. The acquisition is expected to enhance the Company's manufacturing capabilities and expand its product portfolio.

About Neuland Laboratories Limited

Neuland Laboratories Limited is a leading manufacturer of pharmaceutical intermediates and APIs. The Company has a strong track record of delivering high-quality products to its customers. The acquisition of the API Facility near Hyderabad is a significant milestone for the Company and is expected to enhance its manufacturing capabilities and expand its product portfolio. The facility is located in the Hyderabad region and is expected to be operational by the end of the year. The acquisition is expected to enhance the Company's manufacturing capabilities and expand its product portfolio.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 3021 1600, Email: ir@neulandlabs.com

Jenna Palmieri, Neuland Laboratories Inc., USA

Email: jenna@neulandlabs.com

Diwakar Pingle, Investor Relations, Christensen

Tel: +91 22 4215 0210, Email: dpingle@christensenir.com

Disclaimer: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.